ASH 2015 was amazing. So much good news and clarifying news on novel therapies.
Watch here and on the CLL Society website for the news, interviews and updates.
Here are a few teasers:
- Venetoclax (ABT-199) looks very helpful for those who have failed ibrutinib or idelalisib.
- ACP-196, a new BTK inhibitor has stellar results with few side effects.
- Ibrutinib does a super job upfront in the over 65 gang. Should become standard of care frontline.
- The addition of idelalisib to bendamustine and rituximab (BR) greatly improves outcomes, but the use of idelalisib frontline needs to be managed more carefully to get the good results it offers due to increased risk of liver issues.
- Promising results with new signal blockers such as ONO-4059 and duvelisib and TG-1202 and the immune modulator, CC-122 and high dose methylprednisolone (HDMP) and new antibodies and much more.
Stay strong.
Gotta get ready for our flight, I hope. The problem is a broken bathroom door.
BrianIf you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
